ClinicalTrials.gg
Active, not recruitingNCT04892199Updated Sep 25, 2024

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

A Phase 4 interventional study of Semaglutide, 1.34 mg/mL and Semaglutide-placebo in Metabolic Disturbance, Schizophrenia and Type 2 Diabetes, sponsored by Anders Fink-Jensen, MD, DMSci. Active, not recruiting at 3 sites in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Anders Fink-Jensen, MD, DMSci · Phase 4, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Schizophrenia with a site in Denmark — 10 open to participants now, 12 under way, none of them phase 3. Schizophrenia · Denmark.

Planned enrollment
35th of 67
104 · median 108
Started
2021
with 4 others
Phase 4
12 of 79
1 open now
Primary completion
2026-03
later than 2 of 11 live
Registered
59th of 79
by date
Lead sponsor
3 of 79
Anders Fink-Jensen, MD, DMSci

Among the 79 studies in Schizophrenia with a site in Denmark, this one is the 35th largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2021, is one of 12 in phase 4, reaches primary completion later than 2 of the 11 other live ones, and was the 59th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

10 of the 79 studies in Schizophrenia with a site in Denmark are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Schizophrenia with a site in Denmark, or all of them as a file.
02

Study summary

Background and objective:

Clozapine and olanzapine are some of the most effective antipsychotic drugs, but unfortunately, both drugs induce weight gain and conveys a high degree of metabolic disturbances. The antipsychotic-induced side-effects cause a major clinical problem among patients diagnosed with schizophrenia receiving antipsychotic treatment. Limited effects have been demonstrated for counteracting the side-effects by the switch of antipsychotic therapy, non-pharmacological/behavioural interventions or adjunct pharmacological treatments. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA,) is approved for the treatment of type 2 diabetes worldwide. The objective of the study is to investigate effects of semaglutide once-weekly vs. semaglutide placebo once-weekly on the metabolic state in prediabetic or diabetic patients with schizophrenia, who have initiated treatment with clozapine or olanzapine.

Methods and analysis:

Trial design, intervention and participants: The study is a 26-week, double-blinded, randomized, parallel-group, placebo-controlled, good clinical practice (GCP)-monitored, clinical trial. 104 prediabetic or diabetic patients diagnosed with a schizophrenia, age 18 years and 65 years, who have initiated of clozapine- or olanzapine-treatment within 5 years will be included in the study. The patients will be randomized to receive blinded treatment in one of the two study arms; semaglutide once-weekly vs. semaglutide placebo. All participants who complete the 26 weeks of intervention, will be invited for a follow up visit 1.5 yeras after study completion.

The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c). Secondary endpoints include change in body weight, hip and waist circumference, vitals, and plasma levels of insulin, glucose, C-peptid, insulin sensitivity, beta cell function, glucagon, liver function, lipid profile, incretin hormones, lipid profile, bone makers, body composition, bone density and proteomic analyses. Additional endpoints include alcohol, tobacco and drug use, food preferences, psychopathology, activity and quality of life.

03

Conditions studied

  • Metabolic Disturbance
  • Schizophrenia
  • Type 2 Diabetes
  • Clozapine
  • GLP-1
  • Olanzapine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Informed oral and written consent
  2. Diagnosed with schizophrenia according to the criteria of ICD-10 (International Classification of Diseases, World Health Organization (WHO)) or the (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the American Psychiatric Association)
  3. Initiating current treatment with clozapine or olanzapine within 60 months (not PRN ordinations)
  4. Age 18 years to 65 years (both included)
  5. (BMI) ≥25 kg/m2
  6. Diagnosed with prediabetes or type 2 diabetes, after initiation of current treatment with clozapine- or olanzapine, with the following plasma levels: Prediabetes: 35-47 mmol/mol or fasting plasma glucose (FPG) 5.6-6.9 mM or 2-h during 75 mg OGGT 7.8-11.0 mM. The test result has to be confirmed on a different day. Type 2 diabetes: HbA1c 48-57 mmol/mol or fasting plasma glucose (FPG) 6.9-9.9 mM or 2h OGTT > 11 mM (although FPG and HbA1c might still be under the diagnostic range). The test result has to be confirmed on a different day.

Exclusion criteria

Exclusion Criteria:

  1. Acute worsening of psychosis based on a clinical evaluation (score of 6 or 7 on the CGI-S scale)
  2. Coercive measures
  3. Females of who are pregnant, breast-feeding or have intention of becoming pregnant.
  4. Women who are not willing to use adequate during the full length of the study
  5. Patients treated with or other hormone therapy (except oestrogens)
  6. Any active substance abuse or dependence for the past six months (except for nicotine)
  7. Impaired hepatic function (plasma liver transaminases >3 times upper normal limit)
  8. Impaired renal function (serum creatinine >150 μmol/l and/or macroalbuminuria)
  9. Impaired pancreatic function (acute or chronic pancreatitis and/or plasma amylase >2 times upper normal limit)
  10. Cardiac problems defined as decompensated heart failure ( class III/IV), unstable angina pectoris and/or myocardial infarction within the last 12 months
  11. Hypertension with systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg
  12. Any condition that the investigator feels would interfere with trial participation
  13. Receiving any experimental or pre-marketing drug within the last 3 months
  14. Use of weight-lowering pharmacotherapy within the preceding 3 month
  15. Known type 1 diabetes
  16. Suicidal behavior as judged by the investigator and based on clinical evaluation. At all contact with patient attendance possible suicidality will be evaluated according to the guidelines. If the patient is evaluated as suicidal, the person will be excluded from the study and evaluated by a senior consultant in psychiatry, who will take further action.
  17. Plasma > 57 mmol/mol (tested twice) in which case the patient will be excluded from the study and transferred to general practitioner or hospital for diabetic treatment. No diabetic medication is allowed except for the trial medicin.
  18. Any known towards the treatment with semaglutide.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Active comparator
    Semaglutide injection once-weekly

    Drug: Semaglutide, 1.34 mg/mL

  • Placebo comparator
    Semaglutide-Placebo injection once-weekly

    Drug: Semaglutide-placebo

Interventions

  • DrugSemaglutide, 1.34 mg/mL

    Drug page: SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.

  • DrugSemaglutide-placebo

    The semaglutide placebo pens contain "XX-vehicle" (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study.

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c).

    Time frame: 26 weeks

Secondary outcomes

  1. Body weight (Kg)

    Time frame: 26 weeks

  2. Hip and Waist circumference (Cm)

    Time frame: 26 weeks

  3. Incretin hormones (Blood sampling)

    GLP-1, GLP-2 and GIP

    Time frame: 26 weeks

  4. Bone Markers (Blood sampling)

    Calcitonin, Vit-D, Ca, Phosphate, Mg, PTH, PINP, CTX, OC

    Time frame: 26 weeks

  5. Lipid Profile (Blood sampling)

    LDL, HDL, triglycerider, total kolesterol,

    Time frame: 26 weeks

  6. Hormones (blood sampling)

    Insulin, glucagon and C-peptide

    Time frame: 26 weeks

  7. Visceral fat

    DXA scanning

    Time frame: 26 weeks

  8. Android to Gynoid fat ratio

    DXA scanning

    Time frame: 26 weeks

  9. Total body fat

    DXA scanning

    Time frame: 26 weeks

  10. Bone density

    DXA scanning

    Time frame: 26 weeks

  11. Psychopathology

    PANSS-6 interview

    Time frame: 26 weeks

  12. Registration of body movements/level of activity with a sensor

    Activity measurements (approximate for sleep, inactivity, energy expenditure and steps taken by the patient) will be collected continuously by the use of a wearable activity device worn by the patient for 1 week from inclusion day and 1 week at the end of the study

    Time frame: 26 weeks

  13. Reward value of sweet and fatty candy

    Clicker test

    Time frame: 26 weeks

  14. Alcohol use

    Questionnaires: AUDIT

    Time frame: 26 weeks

  15. Tobacco use

    Questionnaires: FNTD

    Time frame: 26 weeks

  16. Drug use

    Questionnaires: DUDIT

    Time frame: 26 weeks

  17. Schizophrenia quality of life scale

    Questionnaire: SQLS

    Time frame: 26 weeks

  18. Psychosocial disability

    Rating GAPD

    Time frame: 26 weeks

  19. Liver function (blood sampling)

    ALT, ALP, AST, trombocytes and bilirubin

    Time frame: 26 weeks

  20. Proteomic analyses (Blood sampling)

    Inflammatory biomarkers and cytokines: IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, MDA, plasma antioxidants uric acid and, vitaminC

    Time frame: 26 weeks

  21. Proteomic analyses (Urine sampling)

    biomarkers for measurement of systemic oxidative stress on DNA and RNA: 8-oxo-7,8-dihydro2´-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanosine (8-oxoGuo

    Time frame: 26 weeks

  22. FIB-4 score

    A non-invasive scoring system for Liver Fibrosis is a non-invasive scoring system based on several laboratory tests (ALT, AST, trombocytes) and age

    Time frame: 26 weeks

  23. Vitals

    Blood pressure and pulse

    Time frame: 26 weeks

  24. Insulin sensitivity and beta cell function

    evaluated by homeostatic model assessment

    Time frame: 26 weeks

07

Study locations

3 sites
  • Psychosis Research Unit, Aarhus University Hospital, Psychiatry,
    Aarhus, 8200, Denmark
  • Psychiatric Centre Copenhagen, Rigshospitalet
    Copenhagen, 2100, Denmark
  • Psychiatric Centre Nordsjaelland, Hillerød
    Hillerød, 3400, Denmark
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication. No end date.

Access criteria: Researchers who provide a methodologically sound proposal

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Mar 2026, 54 months after the start.

Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 54 months is above that.

Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
May 19, 2021
StartActual
Sep 1, 2021
Primary completionEst.
Mar 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04892199
Lead sponsor
Anders Fink-Jensen, MD, DMSci
Responsible party
Anders Fink-Jensen, MD, DMSci (Professor, DMSci, Psychiatric Centre Rigshospitalet) — Sponsor-investigator
First posted
May 19, 2021
Start date
Sep 1, 2021
Primary completion
Mar 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Sep 25, 2024

Study contacts

Anders Fink-Jensen, MD
principal investigator · Psychiatric Centre Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion